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Anthony E Rizzardi1, Arthur T Johnson1, Rachel Isaksson Vogel2, Stefan E Pambuccian1, Jonathan Henriksen1,3,
Amy PN Skubitz1,3, Gregory J Metzger4 and Stephen C Schmechel1,3*Abstract: Immunohistochemical (IHC) assays performed on formalin-fixed paraffin-embedded (FFPE) tissue sections
traditionally have been semi-quantified by pathologist visual scoring of staining. IHC is useful for validating
biomarkers discovered through genomics methods as large clinical repositories of FFPE specimens support the
construction of tissue microarrays (TMAs) for high throughput studies. Due to the ubiquitous availability of IHC
techniques in clinical laboratories, validated IHC biomarkers may be translated readily into clinical use. However, the
method of pathologist semi-quantification is costly, inherently subjective, and produces ordinal rather than
continuous variable data. Computer-aided analysis of digitized whole slide images may overcome these limitations.
Using TMAs representing 215 ovarian serous carcinoma specimens stained for S100A1, we assessed the degree to
which data obtained using computer-aided methods correlated with data obtained by pathologist visual scoring. To
evaluate computer-aided image classification, IHC staining within pathologist annotated and software-classified
areas of carcinoma were compared for each case. Two metrics for IHC staining were used: the percentage of
carcinoma with S100A1 staining (%Pos), and the product of the staining intensity (optical density [OD] of staining)
multiplied by the percentage of carcinoma with S100A1 staining (OD*%Pos). A comparison of the IHC staining data
obtained from manual annotations and software-derived annotations showed strong agreement, indicating that
software efficiently classifies carcinomatous areas within IHC slide images. Comparisons of IHC intensity data derived
using pixel analysis software versus pathologist visual scoring demonstrated high Spearman correlations of 0.88 for
%Pos (p< 0.0001) and 0.90 for OD*%Pos (p< 0.0001). This study demonstrated that computer-aided methods to
classify image areas of interest (e.g., carcinomatous areas of tissue specimens) and quantify IHC staining intensity
within those areas can produce highly similar data to visual evaluation by a pathologist.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1649068103671302.
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SoftwareDespite the exceptional utility of genomics methods in the
discovery phase of experimentation, these technologies re-
quire validation due to problems including misidentifica-
tion of nucleic acid probes on gene expression microarrays
[1,2], non-specificity of probes [3], and the essentially
unavoidable false discovery rates associated with massive
multiple hypothesis testing [4]. Appropriately powered* Correspondence: schme004@umn.edu
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reproduction in any medium, provided the orstudies to validate initial results of genomics studies often
are lacking [5] or fail to confirm initial discovery-phase
results [6], limiting clinical implementation of new disease
biomarkers.
Immunohistochemistry (IHC) is an important tech-
nique for biomarker validation for several reasons. First, it
allows direct visualization of biomarker expression in his-
tologically relevant regions of the examined tissue. This is
an important advantage over “grind and bind” assays in
which tissue is solubilized for biochemical analysis, which
may lead to false negative results if few biomarker-positiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tissue elements [7]. Second, clinical laboratories typically
perform IHC on FFPE tissue sections processed by standard
methods, making potentially available hundreds of millions
of specimens for study [8]. Third, validated IHC assays may
be implemented readily into clinical practice. For example,
genomics methods were used to discover mRNA biomar-
kers capable of subclassifying diffuse large B cell lymphoma
(DLBCL) into prognostically discrete subtypes [9]. Relevant
subsets of these gene products were validated at the protein
level using IHC on large numbers of DLBCL specimens
[10,11], and validated IHC panels are now used clinically.
Traditionally, pathologists have visually scored IHC
data. For example, in the calculation of an HSCORE, a
summation of the percentage of area stained at each inten-
sity level multiplied by the weighted intensity (e.g., 1, 2, or
3; where 0 is no staining, 1 is weak staining, 2 is moderate
staining and 3 is strong staining) of staining is generated
[12]. These analyses are frequently performed on speci-
mens arrayed on stained TMA sections allowing represen-
tation of a sufficiently large number of specimens to for
statistically rigorous testing [13,14]. Tissue specimens are
adequately represented by tissue cores on very few slides
[15,16] minimizing IHC cost and tissue usage, and facilitat-
ing intra-observer, inter-observer and inter-laboratory
studies [10,17-20].
Pathologist visual scoring is fraught with problems due
to subjectivity in interpretation. Automated IHC measure-
ments promise to overcome these limitations. Whole-slide
imaging systems are widely available to convert glass slides
into diagnostic quality digital images [21]. Automated IHC
measurements are precise in ranges of staining that appear
weak to the eye [22] and produce continuous data [23].
Moreover, when automated IHC measurements are pro-
vided to a pathologist during visual scoring, computer-
aided IHC analysis substantially improves both intra- and
inter-observer agreement [20].
In this study, we used TMAs of ovarian serous carcin-
omas stained with an antibody directed against S100A1 to
determine the ability of commercially available software
algorithms (Genie Histology Pattern Recognition software
suite including Genie Training v1 and Genie Classifier v1,
and Color Deconvolution v9, Aperio Technologies, Vista,
CA, USA) to replicate results obtained solely through vis-
ual inspection by a pathologist. Two specific comparisons
were made in this study: a) the segmentation of the digi-
tized tissue images into disease-relevant areas (those con-
taining carcinoma) versus non-relevant areas (stroma and
glass) and b) the quantification of stain intensity within
areas of carcinoma. Specifically, first computer-derived
IHC staining data obtained from both hand-annotated and
Genie-classified areas of carcinoma were compared as a
measure of agreement in tissue classification. Next,
computer-derived IHC staining data from within Genie-classified areas of carcinoma were compared against
pathologist visual scores.
Materials and methods
TMA Construction, IHC, and Pathologist visual scoring
Four TMA slides representing duplicate 0.6 mm core sam-
ples from 215 cases of ovarian serous carcinoma were pro-
vided by the Cheryl Brown Ovarian Cancer Outcomes
Unit (Vancouver, Canada), stained with primary mouse
anti-human S100A1 monoclonal antibody (clone DAK-
S100A1/1; DakoCytomation, Glostrup, Denmark), and
visualized with 3,3-diaminobenzidine (DAB) as previously
described [24]. A total of 54, 54, 77 and 30 cases were
represented by TMA 1, TMA 2, TMA 3, and TMA 4,
respectively. Each TMA spot was examined by a patholo-
gist (S.E.P.) who assigned a score of 0 (no staining),
1 (<10% of malignant cells staining), 2 (10%-50% of malig-
nant cells staining), or 3 (>50% of malignant cells staining)
within carcinomatous areas [24].
Slide digitization, Manual annotation, and
Computer-aided image analysis
Digital images of IHC-stained TMA slides were obtained
at 40x magnification (0.0625 μm2 per raw image pixel)
using a whole slide scanner (ScanScope CS, Aperio) fitted
with a 40x/0.75 Plan Apo objective lens (Olympus, Center
Valley, PA, USA). Images were saved in SVS format
(Aperio), managed with server software (ImageServer,
Aperio), and retrieved with a file management web inter-
face (Spectrum, Aperio).
Under pathologist (S.C.S.) supervision, a technician
(A.E.R.) hand-annotated tumor regions on whole slide
images using Aperio’s annotation software (ImageScope
v10, Aperio). For automated image classification, image
areas from TMA 1 were annotated that represented three
user-defined Image Classes (carcinoma, stroma, and clear
glass) and ranged in morphologic appearance and staining
intensity of DAB and hematoxylin (counterstain). These
image areas were used as input parameters for the histo-
logic pattern recognition training software (Genie Training,
Aperio) to produce a Genie Training Set. The effectiveness
of the Genie Training Set was visualized on TMA 1 image
test regions (TMA spots) using the image classifier algo-
rithm (Genie Classifier, Aperio), which overlaid an image
markup pseudocolored for each Image Class. Annotated
image areas from TMA 1 were adjusted (adding or remov-
ing image areas) for each Image Class to improve the clas-
sifier accuracy. For example, if the Genie Classifier
algorithm over-classified regions of stroma as carcinoma,
additional stromal annotations were added to the Genie
Training algorithm to better represent the stromal Image
Class. This process of adjusting annotations, re-running the
Genie Training algorithm, and visually inspecting pseudo-
colored markup images output by Genie Classifier was
Figure 1 Manual and automated annotations of ovarian serous
carcinoma. Ovarian serous carcinoma TMA spots
immunohistochemically stained for S100A1. Representative lowly
and highly stained spots are shown (A-B). Image data were
processed by both manual pathologist-supervised hand annotations
and automated Genie Histology Pattern Recognition software. Digital
hand annotations are presented as green outlines of carcinoma,
excluding stroma and minimizing background and glass (C-D). These
same TMA spots were classified by Genie as carcinoma (dark blue),
stroma (yellow), and glass (light blue) (E-F).
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oped to classify the TMA 1 slide optimally, as visually vali-
dated by a pathologist (S.C.S.). The optimized Genie
Classifier was then run on TMAs 1-4.
IHC staining was evaluated within carcinomatous areas
of each TMA spot that had been manually annotated,
and a separate analysis was performed on areas from
each TMA spot that had been classified as carcinoma by
the Genie Classifier. As previously described [25,26], the
Color Deconvolution algorithm (Aperio) was used to iso-
late individual stains for quantification: the red, green,
and blue (RGB) OD color vectors were measured for
each stain using default software settings and control
slides stained separately with hematoxylin or DAB. The
average RGB OD values (Hematoxylin: 0.682724,
0.642898, 0.347233; DAB: 0.486187, 0.588538, 0.645945)
were entered into the Color Deconvolution software to
define each stain component in the final analysis settings.
Staining was quantified by two metrics: the percentage of
carcinoma with S100A1 staining (%Pos), and the product
of the staining intensity (OD) multiplied by the percent-
age of carcinoma with S100A1 staining (OD*%Pos). As
previously described, the amount of staining present is
linearly related to OD [26].
Statistical analysis
Duplicate spots were summarized as a single score for each
case by randomly selecting one of the replicates. In order
to compare pathologist hand and Genie automated annota-
tions, which represent the same clinical measure on the
same scale, Bland-Altman plots were used [27]. This scat-
terplot of the difference between methods, with reference
lines at the mean difference and mean difference ± 2*-
standard deviation of the differences, allows for an assess-
ment of agreement rather than just a measure of
correlation. Comparisons of both %Pos and OD*%Pos
values by method were conducted. Spearman’s correlation
was calculated to compare pathologist visual scores versus
%Pos and OD*%Pos values. Each comparison was made
within each of the four TMAs. Additionally, we pooled all
of the data to compare the %Pos and OD*%Pos values by
pathologist score using Wilcoxon rank-sum tests.
Results
Hand annotation versus Genie image classification of
carcinoma
Representative TMA spots that had been stained for
S100A1 by IHC were used for the analysis in this study are
shown in Figure 1A,B. Examples of pathologist-directed,
technician hand-annotation of areas of carcinoma, used in
subsequent training and analysis, are shown in Figure 1C,
D. The Genie Training Set algorithm was optimized and
validated on TMA 1, a process that required one hour of
pathologist time in addition to ten hours of techniciantime. After optimization, the Genie Classifier algorithm
was then run on all spots from TMAs 1-4 to classify areas
of carcinoma, stroma and glass (Figure 1E,F). For both
hand annotated and Genie classified carcinomatous areas,
the Color Deconvolution algorithm was run to obtain %Pos
and OD*%Pos data for DAB staining. The process of gener-
ating final data, which involved image quality control - for
example to exclude damaged TMA spots from analysis -
and organizing data output from Color Deconvolution,
required an average of 3.5 hours per TMA, or 14 hours in
total, of technician time.
There was strong agreement between data resulting from
hand-annotation of carcinoma and data obtained after auto-
mated Genie classification of carcinoma (Figures 2 and 3).
There was stronger agreement between the pathologist
TMA 1 TMA 2
TMA 3 TMA 4
Figure 2 Bland-Altman plots comparing automated IHC measurements (%Pos) by Hand Annotation or Genie Annotation by TMA.
Bland-Altman difference plots between hand-annotated carcinomatous areas and Genie-annotated carcinomatous areas were generated for %Pos
obtained using the Color Deconvolution algorithm. Data are displayed separately for TMA 1 on which the software methods were trained and
TMAs 2-4 which were independent data sets. Red lines indicate mean and ± 2*standard deviation.
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metric, evidenced by the lower variability in the mean
difference in comparison with the %Pos metric.
Pathologist visual scoring in carcinoma versus Automated
IHC measurement in Genie-classified carcinomatous areas
Using glass slides, a pathologist scored TMA spots for
the percentage of positively stained carcinoma on a scale
of 0-3+ as shown in representative spots covering the
full scoring range in Figure 4A-D. For the 215 tumors
in this study, scoring the TMA spots required 10 hours
of pathologist time. In areas classified by Genie as car-
cinoma (Figure 4E-H), the Color Deconvolution algo-
rithm individually analyzed DAB staining (deconvoluted
by its RGB color components; Figure 4I-L) and %Pos
and OD*%Pos data were obtained. As in Figure 1E,F,
only the areas of carcinoma (pseudocolored as dark blue
in Figure 1E,F and Figure 4E-H) were considered; areasof stroma and glass (yellow and light blue, respectively,
in Figure 1E-F and Figure 4E-H) did not contribute to
the final IHC data. Data representative of OD*%Pos are
illustrated as a heatmap in Figure 4M-P (gray = image
areas not annotated by Genie as carcinoma and there-
fore not considered; blue = no staining, yellow = low
intensities, orange =medium intensities, and red = high
intensities in Genie-annotated carcinomatous areas con-
sidered). There was high correlation between pathologist
visual scoring and %Pos data obtained using image ana-
lysis software for all TMAs, with Spearman correlations
of 0.89, 0.78, 0.90 , and 0.90 for TMAs 1, 2, 3, and 4,
respectively (all p< 0.0001; box plots of data shown in
Figure 5). There was slightly higher correlation between
pathologist visual scoring and OD*%Pos data, with
Spearman correlations of 0.91, 0.81, 0.90, and 0.91, for
TMAs 1, 2, 3, and 4, respectively (all p< 0.0001; box
plots shown in Figure 6).
TMA 1 TMA 2
TMA 3 TMA 4
Figure 3 Bland-Altman plots comparing automated IHC measurements (OD*%Pos) by Hand Annotation or Genie Annotation by TMA.
Bland-Altman difference plots between hand-annotated carcinomatous areas and Genie-annotated carcinomatous areas were generated for OD*%
Pos obtained using the Color Deconvolution algorithm. Data are displayed separately for TMA 1 on which the software methods were trained and
TMAs 2-4 which were independent data sets. Red lines indicate mean and ± 2*standard deviation.
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bined data (TMAs 1-4) from digital image analysis, reveal-
ing high correlation between pathologist visual scoring and
%Pos (Spearman correlation 0.88, p< 0.0001) and OD*%
Pos (Spearman correlation 0.90, p< 0.0001). There were
significant differences in the median values for both
metrics (%Pos and OD*%Pos) by pathologist score. Most
notably, there were significant differences in computer-
derived data corresponding to spots scored by the patholo-
gists as “0” and “1” for both %Pos (p< 0.0001) and OD*%
Pos (p< 0.0001).
Discussion
In this report we have demonstrated that commercially
available software algorithms to classify disease-relevant
tissue areas (Genie Histology Pattern Recognition) and
quantify IHC staining within those areas (Color Deconvo-
lution) effectively replicated IHC data produced by manualclassification of image areas and pathologist visual scoring
for S100A1 in ovarian serous carcinoma. Other software
algorithms also provide data highly correlated with path-
ologist scores, e.g., human epidermal growth factor recep-
tor 2 (HER2) [28-34], estrogen receptor [35-39] and
progesterone receptor [37-39] in breast cancer, DNA mis-
match repair proteins in esophageal cancer [40], and
epidermal growth factor receptor signaling molecules in
colon cancer [41], among other biomarkers.
In this report, we provide important additional informa-
tion regarding comparisons between digital data based
solely on IHC-positive area (%Pos) and data combining
area and staining intensity (OD*%Pos). The OD*%Pos
metric provided better visual correlation between hand-
annotated areas and Genie-annotated areas (Figure 4).
Further, the OD*%Pos metric provided slightly higher cor-
relation between digital IHC data and pathologist visual
scoring. Of note, the study pathologist (S.E.P.) scored
Figure 4 Representative comparisons of pathologist visual scoring with automated IHC measurement. Ovarian serous carcinoma TMA
spots stained for S100A1 were interpreted by pathologist visual scoring as 0 (no staining), 1 (<10% of carcinoma staining), 2
(10%-50% of carcinoma staining), or 3 (>50% of carcinoma staining). Representative spot for each score is shown as A-D; each column shows the
identical TMA spot processed by digital methods. Genie Histology Pattern Recognition software classified tissue areas into carcinoma (dark blue),
stroma (yellow), or glass (light blue) (E-H). Color Deconvolution software individually analyzed DAB staining (deconvolved by its RGB color
components; I-L), and measured staining intensity only within areas classified as carcinoma. Pseudocolors represent staining intensity in shown as
M-P (gray = image areas not annotated by Genie as carcinoma and therefore not considered; blue = no staining, yellow = low intensities,
orange =medium intensities, and red = high intensities in Genie-annotated carcinomatous areas considered).
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described in the Materials and Methods section, rather
than by using a method such as HSCORE, which sum-
mated the percentage of area stained at each intensity level
multiplied by the weighted intensity (e.g., 1, 2, or 3) [12].
Thus, it is unclear from our data why OD*%Pos performedsomewhat better than %Pos. We speculate that, since the
human eye is more sensitive to higher intensity IHC stain-
ing [22], the estimation by eye of area IHC-stained likely
inherently encompasses a component of staining intensity.
We additionally provide information regarding time con-
servation for pathologists using digital imaging methods for
2 AMT1 AMT
TMA 3 TMA 4
Figure 5 Automated IHC measurements (%Pos) versus pathologist visual score displayed separately for each TMA. Box plots of %Pos
data generated using Genie Histology Pattern Recognition software and Color Deconvolution software within carcinomatous areas (vertical axes)
versus pathologist visual score (horizontal axes). Data are displayed separately for TMA 1 on which the software methods were trained and TMAs
2-4 which were independent data sets.
Rizzardi et al. Diagnostic Pathology 2012, 7:42 Page 7 of 10
http://www.diagnosticpathology.org/content/7/1/42obtaining IHC data. While acknowledging that generating
the automated IHC measurements within Genie-classified
areas of carcinoma required 24 hours of technician time,
10-fold less pathologist time was required versus visual
examination of each spot on TMAs 1-4. Greater efficien-
cies in the use of pathologists’ time are needed as patholo-
gists are experiencing increasing demands on their time
due to higher clinical practice volumes, greater complexity
of testing, and industry-wide shortages in available employ-
ees [42]. Although we did not measure pathologist time on
a per-TMA spot basis in this study, a previous study indi-
cates that per-spot time required for pathologist visual
scoring of TMAs markedly increases as the number of
spots to be analyzed increases [43]. Although limited data
are available to assess pathologist fatigue on data quality,
fatigue is postulated as a potential source of error in visual
interpretation of IHC stained tissue sections [17]. To the
contrary, automated analysis is objective and temporally
linear regardless of the number of spots analyzed [43].Although IHC biomarker studies widely use pathologist
visual scoring, automated IHC measurement offers several
additional advantages. First, pathologist visual scoring is
fraught with data quality problems. The human eye is least
accurate at detecting differences under conditions of weak
staining at which IHC is most linearly related to target
antigen concentration [22]. Consequently, regions of nega-
tive and high-positive intensities may be overcalled leading
to artificially-produced bimodal score distributions [23].
While pathologist-derived data have good to excellent
intra- and inter-observer reproducibility [18-20], estima-
tion of percentages of areas stained has only poor to good
reproducibility [19]. Digital methods may provide more re-
liable data. For example, automated HER2 IHC measure-
ments are more comparable to consensus visual scores by
multiple expert pathologists, and to HER2 gene amplifica-
tion data, than are individual pathologists’ subjective visual
scores [44]. Since consensus scoring by experts is impracti-
cal in routine practice, automated IHC measurement may
TMA 1 TMA 2
TMA 3 TMA 4
Figure 6 Automated IHC measurements (OD*%Pos) versus pathologist visual score displayed separately for each TMA. Box plots of OD*
%Pos data generated using Genie Histology Pattern Recognition software and Color Deconvolution software within carcinomatous areas (vertical
axes) versus pathologist visual score (horizontal axes). Data are displayed separately for TMA 1 on which the software methods were trained and
TMAs 2-4 which were independent data sets.
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inter-observer agreement is improved by providing pathol-
ogists with computer-aided IHC measurements during the
visual scoring process [20,45]. Software algorithms such as
Genie and Color Deconvolution may be “locked” such that
all subsequent images are analyzed using the same para-
meters. Second, the automated methods demonstrated in
this report also produced continuous variable data. Recent
studies indicate that continuous variable data may allow
identification of IHC cut-points of prognostic relevance
that are either undetected [46] or are less statistically sig-
nificant [23,34,47] by visual scoring. Third, digital methods
support multigene expression studies at the protein level.
Methods exist to multiplex IHC using immunofluores-
cence [48], destaining and restaining protocols [49], mul-
tiple chromagens [50,51], and combining data fromadjacent tissue sections [52,53]. Based on these and other
studies, automated methods will likely become standard
clinical practice.
Conclusions
This study demonstrated the effectiveness of optimized
histology pattern recognition and automated IHC measure-
ment algorithms to reproduce manual annotations and
visual evaluation by a pathologist. This approach used
TMAs in which tissue cores were obtained under the direc-
tion of a pathologist from areas containing exclusively
tumor. A limited number of tissue cores adequately repre-
sent protein expression in tumor specimens [15,16]. Never-
theless, methods of quality control are required in final
data analysis to exclude tissue areas with artifacts such as
tissue folds, and tissue regions not of interest such as
Rizzardi et al. Diagnostic Pathology 2012, 7:42 Page 9 of 10
http://www.diagnosticpathology.org/content/7/1/42admixed benign tissue elements in the analysis of carcin-
oma. It is important to note that we have found, in data not
shown, that each combination of tissue type and IHC stain
requires separate Genie optimization.
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